A number of other equities analysts also recently issued reports on BLFS. BidaskClub upgraded Xilinx from a hold rating to a buy rating in a report on Saturday, June 29th. Maxim Group set a $24.00 price objective on BioLife Solutions and gave the stock a buy rating in a report on Wednesday, May 22nd. Northland Securities assumed coverage on Greenlane in a report on Monday, May 13th. They issued an outperform rating and a $23.00 price objective for the company. Finally, Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. BioLife Solutions has a consensus rating of Buy and a consensus price target of $17.80.
BLFS opened at $16.93 on Tuesday. The business has a fifty day moving average price of $17.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50. The company has a market capitalization of $324.10 million, a P/E ratio of 101.41 and a beta of 1.31. BioLife Solutions has a 12-month low of $9.15 and a 12-month high of $26.35.
In other news, VP James Mathers sold 2,500 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $17.94, for a total transaction of $44,850.00. Following the completion of the transaction, the vice president now directly owns 19,884 shares in the company, valued at $356,718.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $17.56, for a total value of $52,680.00. Following the transaction, the vice president now owns 44,074 shares of the company’s stock, valued at $773,939.44. The disclosure for this sale can be found here. Insiders have sold 216,871 shares of company stock valued at $3,826,019 over the last 90 days. Corporate insiders own 27.00% of the company’s stock.
Several large investors have recently modified their holdings of BLFS. Cadence Capital Management LLC increased its holdings in BioLife Solutions by 1.8% in the 1st quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock worth $3,493,000 after buying an additional 3,439 shares in the last quarter. FMR LLC bought a new stake in BioLife Solutions in the 1st quarter worth about $2,684,000. Granite Investment Partners LLC increased its holdings in BioLife Solutions by 25.5% in the 1st quarter. Granite Investment Partners LLC now owns 103,109 shares of the medical equipment provider’s stock worth $1,845,000 after buying an additional 20,947 shares in the last quarter. Ranger Investment Management L.P. bought a new stake in BioLife Solutions in the 4th quarter worth about $1,108,000. Finally, Laurion Capital Management LP increased its holdings in BioLife Solutions by 74.0% in the 1st quarter. Laurion Capital Management LP now owns 84,944 shares of the medical equipment provider’s stock worth $1,520,000 after buying an additional 36,136 shares in the last quarter. Hedge funds and other institutional investors own 45.76% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: How to trade on quiet period expirations
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.